PwC's Health Industries

PwC's Next in Health

Health EN ↓ 77 episodes

Hosted by Glenn Hunzinger, US Health Industries Leader, the Next in Health podcast series offers insights on the most important issues facing pharma, medtech, and healthcare. PwC business leaders discuss the latest trends and their impact on health industries, whether it is policy, AI, innovation, care delivery, business model reinvention, or bold moves shaping the future. If it is happening in health industries, we are talking about it.

Be sure to visit the podcast's website and support the creator: pwc.com

Author

PwC's Health Industries

Category

Health

Podcast website

pwc.com

Latest episode

Nov 13, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

2026 Midterm Election Results: What's Next for US Healthcare Policy? 13.11.2026

What do the 2026 midterm election results mean for the future of US healthcare? With Democrats taking control of Congress and a Republican White House, healthcare affordability, access and industry oversight are expected to remain in focus. But how much policy change is actually possible? In this episode of Next in Health, PwC's Glenn Hunzinger is joined by Kelly Griffin, Tamil Sriram and Phi...

Bringing medtech innovation to market (Part 2) 15.10.2026

Bringing medtech innovation to market requires more than a breakthrough technology. It takes the right capital, evidence, reimbursement strategy, and path to scale. In this episode of PwC’s Next in Health, Glenn Hunzinger and Brent Hill continue their conversation with Darshana Zaveri, co-founder and managing partner of Catalyst Health Ventures, and Geoff Pardo, general partner at Gilde Healthcare...

The next wave of medtech innovation (Part 1) 08.10.2026

Medtech innovation is accelerating, creating new possibilities for how and where patients receive care. In this episode of PwC’s Next in Health, Glenn Hunzinger and Brent Hill are joined by Darshana Zaveri, co-founder and managing partner of Catalyst Health Ventures, and Geoff Pardo, general partner at Gilde Healthcare, for part one of a two-part conversation on the next wave of medtech innovation...

Behind the Numbers 2027: Understanding what's driving healthcare costs—and what it means for the future of healthcare 30.07.2026

Healthcare affordability continues to be one of the defining challenges facing the industry. In this episode of PwC's Next in Health, Glenn Hunzinger is joined by Thom Bales, Derek Skoog, and Philip Sclafani to discuss the findings from PwC's Behind the Numbers 2027 report and the forces driving medical cost trends toward 9% in 2027. From AI-enabled documentation and provider reimburseme...

US Medtech Deals Midyear Outlook 2026: Why companies are investing through uncertainty 25.06.2026

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with James Woods, PwC's US MedTech Leader, about the forces shaping MedTech dealmaking in 2026. Despite capital market pressures, supply chain challenges, and geopolitical uncertainty, companies continue to invest in innovation, portfolio transformation, and growth opportunities. The conversation explores where capital is flowing...

US Health Services Deals Midyear Outlook 2026: Why investors are focusing on resilience and value creation 25.06.2026

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with Dan Farrell, PwC's Health Services Deals Leader, about the forces shaping health services dealmaking in 2026. Despite ongoing reimbursement uncertainty, rising medical costs, and operational pressures, investors continue to deploy capital into assets with strong fundamentals and clear value creation opportunities. The conver...

US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into Growth 24.06.2026

Glenn Hunzinger, PwC's US Health Industries Leader, speaks with Dan Farrell, PwC's Health Services Deals Leader, about the forces shaping health services dealmaking in 2026. Despite ongoing reimbursement uncertainty, rising medical costs, and operational pressures, investors continue to deploy capital into assets with strong fundamentals and clear value creation opportunities. The conver...

What to Watch in US Health Policy Before the 2026 Midterms 04.05.2026

As the 2026 midterm elections approach, healthcare leaders are asking whether this is just another policy cycle or a more pivotal moment in an increasingly complex and fragmented landscape. In this episode of PwC’s Next in Health, Glenn Hunzinger speaks with Kelly Griffin and Philip Sclafani about how shifting policy dynamics, persistent cost pressures, and rapid industry transformation are reshap...

Strategies for accessing funding and managing risk in rural health transformation 17.03.2026

With $50 billion flowing through the Rural Health Transformation Program (RHTP), healthcare leaders are questioning whether this marks short term stabilization or a real opportunity to redesign rural care. In this episode of PwC’s Next in Health, Glenn Hunzinger speaks with Thom Bales and Jill Olmstead about how states are deploying funds, how accountability is shaping execution, and what sustaina...

2026 Healthcare Investment Trends 09.02.2026

From the JPM Healthcare Conference in San Francisco, Glenn Hunzinger, PwC’s Health Industries Leader, speaks with Jeremy Gelber, Partner at Vitruvian Partners, and Claire Love, Principal in PwC’s Deals Strategy practice to explore where healthcare investment momentum is building for 2026, how technology is reshaping value creation, and what investors are watching as care models, consumer behavior,...

Where will growth emerge in health over the next 10 years? 29.01.2026

From the JPM Healthcare Conference in San Francisco, Glenn Hunzinger brings together Sunil Patel of Merck and Sumit Khedekar of Citigroup for a conversation about where growth in the pharmaceutical and biotech industry is headed over the next five to ten years. They explore how scientific innovation, global sources of capital and talent, and a more forward looking approach to risk taking are shapi...

Deals Outlook 2026: What’s ahead for medtech 07.01.2026

Join Glenn Hunzinger and James Woods as they discuss what to expect for medtech dealmaking in 2026, including why buyers are poised to return, how technology is reshaping portfolios, and where investors are focusing to drive future growth. Discussion highlights: Medtech M&A is expected to rebound in 2026 as market conditions improve and capital remains available Buyers are staying selective, p...

Deals Outlook 2026: What’s ahead for pharma and life sciences 19.12.2025

Tune in as Glenn Hunzinger and Roel van den Akker share their outlook for pharmaceutical and life sciences dealmaking in 2026. They discuss improving market conditions, innovation driven growth, and how upcoming loss of exclusivity is shaping deal strategy.    Discussion highlights:  Strong innovation, healthy balance sheets, and improving capital markets support a positive outlook for 2026  M&amp...

Deals Outlook 2026: What’s ahead for health services 19.12.2025

Join Glenn Hunzinger and Dan Farrell as they discuss why 2026 could mark a rebound year for health services dealmaking—driven by higher-quality assets, improving market conditions, and the growing role of technology and AI. They explore how investors are rethinking value creation, from tech-enabled care models to carve-outs and IPOs.   Discussion highlights: Stronger earnings, cash flows, and tech...

Reinventing Healthcare - Seizing the $1 Trillion Breakthrough 21.10.2025

What will healthcare look like a decade from now? Host Glenn Hunzinger is joined by Greg Rotz, Pharmaceutical and Life Sciences Advisory Leader and Thom Bales, Principal, Health Services Advisory Leader, as they dive into the future of health—one driven by smarter tech, empowered consumers, and breakthrough science. From reimagining chronic care to building new business models, discover the mindse...

The One Big Beautiful Bill: What It Means for the Future of U.S. Healthcare 01.08.2025

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, sits down with Nichole Montgomery, Shannon O’Shea, and Phil Sclafani to unpack the sweeping implications of the newly signed One Big Beautiful Bill Act (OBBBA). With nearly a third of the bill dedicated to healthcare, the team explores how this landmark legislation will reshape coverage, funding, and delivery across the payer, provider, a...

Strategic Dealmaking in Health: Navigating Midyear Trends in 2025 10.07.2025

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, connects with Nick Donkar, PwC’s U.S. Health Services Deals Leader, and Roel Van den Akker, PwC’s Pharma and Life Sciences Deals Leader, to discuss the 2025 midyear deals outlook across health services and pharma and life sciences. They explore how macroeconomic trends, regulatory pressures, and evolving investment strategies are shaping...

Taking a closer look at the Most Favored Nation Pricing Executive Order 03.06.2025

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, and Phil Scalfani, PwC’s Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration’s executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader...

Navigating the FDA disruption: 4 key actions for pharma 23.05.2025

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, connects with Matt Rich, PwC’s Pharma and Life Sciences R&D Leader, to unpack the recent disruption at the FDA and what it means for the pharmaceutical and biotech sectors. They discuss how companies can stay agile in the face of regulatory uncertainty, avoid preventable delays, and take practical steps to move programs forward with c...

Strategic Shifts: Navigating China's Biotech Boom and Its Impact on US Pharma 22.05.2025

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader and Roel van den Akker, PwC’s Pharma and Life Sciences Deals Leader discuss the rapid rise of China’s biotech industry and what it means for U.S. pharmaceutical companies. They discuss the evolving role of Chinese biotech in the global innovation landscape and share perspectives on how U.S. pharmaceutical companies can thoughtfully assess...

Navigating Healthcare’s Next Chapter Under the Trump Administration 23.04.2025

Disclaimer: This episode was recorded on April 11th, 2025, and reflects the information available at the time of recording. As we know, America is in motion here, and so subsequent updates may not be reflected in this discussion as things continue to evolve and change.  Tune in as PwC specialists from across the health industry share their insights on how recent policy shifts under the Trump admin...

Next in Pharma: The 2025 Outlook—The Future is Now 19.03.2025

Tune in as PwC's Pharmaceutical & Life Sciences Advisory Leader, Greg Rotz reflects on key market dynamics and explores how pharma leaders can tackle challenges including the $400 billion patent cliff, increasing competition, drug pricing pressures, and transformative disruptions shaping the industry. Discussion highlights: Understanding the scale and implications of the upcoming patent c...

Next in Health: The 2025 Outlook for Health Services 17.02.2025

Tune in as PwC specialists discuss the 2025 healthcare outlook, reflecting on 2024’s significant events and exploring how payers and providers can navigate rising costs, scrutiny, AI advances, and policy shifts with resilience and adaptability.  Topics include: Medicare and Medicaid drive industry growth amid rising competition, market exits, M&A, AI adoption, and policy challenges. AI's...

Health Industries: U.S. Deals Outlook for 2025 and Beyond 06.01.2025

Tune in to listen as PwC’s leaders Roel van den Akker and Nick Donkar provide insights into the 2024 deals landscape and offer a preview of what lies ahead. Topics include: Key topics include: A look back at M&A activity in health industries in 2024 The challenges and potential impediments that could affect deal volumes in the coming year How artificial intelligence and tech innovations are re...

PwC’s 2024 US Healthcare Climate Survey 18.12.2024

Tune in as authors of PwC's U.S. Healthcare Climate Survey discuss key findings and provide insights into understanding healthcare organizations' responses to climate change, the integration of climate strategies, and the challenges faced in implementation. Key topics include: The survey's background, focus, and objectives that address the prioritization of climate strategies by hea...

Listen to the PwC's Next in Health podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.